Ischaemic heart disease (IHD) is the leading cause of death and disability worldwide 1 . ST-segment elevation myocardial infarction (STEMI) is a major emergency manifestation of IHD, usually precipitated by acute thrombotic occlusion of a main coronary artery at the site of a ruptured atherosclerotic plaque. Reperfusion, using primary percutaneous coronary intervention (PPCI), is the treatment of choice for reducing the size of a myocardial infarction (MI), preserving left ventricular (LV) systolic function, and preventing the onset of heart failure in patients with STEMI. However, despite timely PPCI, morbidity and mortality remain substantial in patients with STEMI, with death reported in 7% and heart failure in 22% of patients at 1 year after the event 2 . Although mortality of patients with STEMI has declined over the past 10-15 years, owing to improvements in secondary preventive therapy, the number of patients who develop heart failure has increased. The size of an MI is a major determinant of LV systolic function and the propensity for developing heart failure; therefore, novel therapies that reduce infarct size and can be administered as adjuncts to PPCI are needed to improve patient survival and prevent the onset of heart failure.
. Although mortality of patients with STEMI has declined over the past 10-15 years, owing to improvements in secondary preventive therapy, the number of patients who develop heart failure has increased. The size of an MI is a major determinant of LV systolic function and the propensity for developing heart failure; therefore, novel therapies that reduce infarct size and can be administered as adjuncts to PPCI are needed to improve patient survival and prevent the onset of heart failure.
In patients with IHD and severe multivessel coronary disease, the heart is more commonly revascularized using CABG surgery. This operation can be complicated by perioperative myocardial injury (PMI), which can result from acute global myocardial ischaemia-reperfusion injury (IRI) when going onto and coming off cardiopulmonary bypass 3, 4 , and can lead to LV systolic impairment, the onset of heart failure, and risk of death after surgery. Owing to the ageing population and the growing prevalence of comorbidities (such as diabetes mellitus, obesity, hypertension, and valve disease), patients undergoing CABG surgery are at a higher risk of PMI than ever before. The extent of PMI is a critical determinant of clinical outcomes after surgery [5] [6] [7] . Novel therapies are, therefore, required for this patient group to reduce the magnitude of PMI, preserve LV systolic function, and prevent the onset of heart failure. Notably, myocardial injury and cardiomyocyte death after CABG surgery are caused by acute IRI similarly to revascularization after STEMI; however, factors such as direct handling of the heart, coronary microembolization, and inflammation also contribute and might influence effectiveness of therapies.
For both patient groups, 'ischaemic conditioning' provides an endogenous strategy that can protect the heart from the detrimental effects of acute IRI, and which has the potential to improve clinical outcomes in patients with IHD. Ischaemic conditioning is the term given to a number of related endogenous cardioprotective strategies, all based on rendering the heart toler ant to acute IRI by conditioning it with one or more brief cycles of ischaemia and reperfusion (FIG. 1) . In this Review, we provide an overview of the various types of ischaemic conditioning and pharmacological cardioprotection. The challenges of translating these methods into the clinical setting are highlighted, and future therapies that have the potential to improve clinical outcomes in patients with IHD are discussed.
Myocardial reperfusion injury
In 1985, Braunwald & Kloner wrote that "myocardial reperfusion may be viewed as a double-edged sword" 8 . Although strategies are in place to minimize acute myocardial ischaemic injury for patients presenting with an acute STEMI or in patients undergoing cardiac surgery, 'myocardial reperfusion injury' -the myocardial injury and cardiomyocyte death that paradoxically occurs with the acute reperfusion of ischaemic myocardium -remains untreated in both these patient groups [9] [10] [11] [12] . Therefore, although myocardial reperfusion is essential to salvage viable myocardium, it comes at a price.
In 1960, Jennings et al. first suggested that reper fusion might hasten the necrotic process of cardio myocytes irreversibly injured during ischaemia 13 . More contentious was the notion that reperfusion could induce the death of cardiomyocytes 8 that had been only reversibly injured during ischaemia. However, the experi mental and clinical evidence for myocardial reperfusion injury has been convincingly provided by the observation that a therapeutic intervention applied solely at the onset of reperfusion can reduce MI size 10, 12 .
Myocardial reperfusion injury can manifest in four different forms. Reperfusion-induced arrhythmias can be induced in patients with STEMI on acutely reperfusing ischaemic myocardium through thrombo lysis or PPCI and comprise idioventricular rhythm and ventricular arrhythmias. The majority of these arrhythmias are self-terminating or are easily managed. Myocardial stunning is a reversible contractile dysfunction that also occurs on acutely reperfusing ischaemic myocardium, and is believed to result from oxidative stress and intracellular calcium overload in cardiomyocytes. Myocardial stunning is usually self-terminating, with myocardial function recovering within days or weeks. Microvascular obstruction, the third form of
Key points
• Currently, no treatment has been proven to be effective for preventing 'myocardial reperfusion injury' -the death of cardiomyocytes that paradoxically occurs when reperfusing ischaemic myocardium • One or more brief cycles of ischaemia and reperfusion can protect the heart from acute myocardial infarction and myocardial reperfusion injury -a phenomenon termed 'ischaemic conditioning' • Ischaemic conditioning can be applied either directly to the heart or from afar; that is, to a remote organ or tissue (such as an arm or a leg) • Investigation of signalling pathways underlying ischaemic conditioning has identified molecular targets for pharmacological manipulation -a therapeutic strategy termed 'pharmacological cardioprotection' • Proof-of-concept clinical studies have shown mixed results of ischaemic conditioning in cardiac surgery and percutaneous coronary intervention; more consistently positive results have been observed in acute myocardial infarction • The results of large, multicentre, randomized, controlled clinical trials of ischaemic conditioning on clinical outcomes after cardiac surgery have highlighted the challenges in translating cardioprotection into clinical practice This schema depicts the different forms of ischaemic conditioning, and their timing with respect to the index myocardial ischaemia and reperfusion episode. The clinical settings in which they have been tested (dark shading) or the clinical settings in which there is potential for application (light shading) are described below. Delayed preconditioning with one or more brief episodes of ischaemia-reperfusion can be delivered 48-72 h before the index ischaemic event, whereas classical preconditioning has to be delivered within 3 h of the index ischaemic episode. Perconditioning can be delivered after the onset of index myocardial ischaemia, but before reperfusion, whereas postconditioning has to be initiated within 1 min of reperfusion to be effective. Delayed postconditioning, which can be delivered up to 15-30 min into reperfusion, has not yet been investigated in the clinical setting, and remains a preclinical observation. PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction. myocardial reperfusion injury, was originally defined by Krug et al. in 1966 as the "inability to reperfuse a previously ischaemic region" 14 , and its histological features were character ized by Kloner et al. in 1974 in the canine heart 15 . The aetiology of micro vascular obstruction is multifactorial and has been attributed to a number of events, including capillary damage with impaired vasodilatation, external capillary compression by endothelial cells, cardiomyocyte swelling, micro embolization of friable material released from the athero sclerotic plaque, platelet microthrombi, and neutrophil plugging 16, 17 . Among patients with STEMI, micro vascular obstruction has been reported to occur in up to 60% of patients with post-PPCI normal coronary flow (TIMI 3) within the infarct-related artery 17, 18 . The presence of microvascular obstruction is associated with adverse LV remodelling, and poor clinical outcomes after PPCI. Lethal myocardial reperfusion injury is the main cause of reperfusion-induced death of cardio myocytes that have been reversibly injured, and can contribute to up to 50% of the final MI size. Cytosolic and mitochondrial calcium overload, oxidative stress, and rapid restoration of intracellular pH, which result in the opening of the mitochondrial permeability transition pore (MPTP) and irreversible cardiomyocyte hypercontracture 19 , have been shown to trigger lethal myocardial reperfusion injury. However, a number of other factors contribute, including osmotic overload, gap-junction changes, and inflammatory signalling. Crucially, no effective therapy exists for reducing lethal myocardial reperfusion injury in patients with STEMI who have undergone revascularization procedures or after cardiac surgery.
Ischaemic preconditioning
While investigating the cumulative effects of short periods of ischaemia on myocardial adenine nucleotides, lactate, and MI size, Murry, Reimer, and Jennings made the intriguing discovery that four 5 min cycles of alternating occlusion and reflow of the left anterior descending (LAD) coronary artery, applied immediately before 90 min of occlusion and 3 days of reperfusion, resulted in a 75% reduction in MI size in the canine heart 20, 21 . This seminal observation, termed ischaemic preconditioning (IPC), has been replicated in all species tested, including humans, and can be readily applied to other organs and tissues [22] [23] [24] . After reperfusion, IPC remains the most powerful intervention for reducing MI size in ischaemic hearts. Over the past 3 decades, almost 9,000 papers have been published on this topic.
Mechanisms of action
The IPC stimulus has been shown to induce two distinct windows of cardioprotection. The first window occurs immediately after the IPC stimulus and lasts 2-3 h (termed 'classical IPC' or 'acute IPC'), after which the effect wanes and disappears. The second window follows 12-24 h later, and lasts 48-72 h (termed 'delayed IPC' or 'second window of protection') 25, 26 . Despite intensive investigation, the actual mechanisms that mediate this cardioprotective effect remain incompletely understood, although a large number of signalling pathways underlying IPC have been identified. Only a very simplified overview can be provided in this Review (more-comprehensive reviews of the subject have been published previously 22, 23, 27 ). In brief, the IPC stimulus, made up of cycles of brief ischaemia and reperfusion, initiates production of a number of autacoids (such as acetylcholine, adenosine, bradykinin, endothelin, and opioids) by cardiomyocytes. These autacoids bind to their respective receptors on the plasma membrane of cardiomyocytes to stimulate a number of signalling pathways that convey a cardio protective signal to the mitochondria. In the mitochondria, signalling reactive oxygen species (ROS) are generated and activate protein kinases such as Akt, Erk1/2, protein kinase C, and tyrosine kinase, which provide the 'memory' . This process allows the cardioprotective effect to last up to 2-3 h (in classical IPC). In delayed IPC, these protein kinases activate transcription factors, such as AP-1, hypoxic-inducible factor 1α, nuclear factor κB, nuclear factor erythroid 2-related factor 2 (also known as Nrf2), and signal transducer and activator of transcription (STAT) 1/3, which facilitate the synthesis of 'distal mediators' , such as prostaglandin G/H synthase (also known as COX-2), heat shock proteins (such as Hsp72), and inducible nitric oxide synthase, which in turn induce the cardioprotective effect 12-24 h after the IPC stimulus 28 . In the prevention of myocardial reperfusion injury, IPC has been shown to recruit prosurvival signalling pathways at the onset of reperfusion, including the Reperfusion Injury Salvage Kinase (RISK) pathway (comprising Akt and Erk1/2) 29 and the Survivor Activator Factor Enhancement (SAFE) pathway (comprising TNFα and JAK-STAT3) 30 . The final processes of cardioprotection in classical and delayed IPC remain unclear, although some investigators have hypothesized that preservation of mitochondrial function with less calcium overload, attenuated ROS production, and MPTP inhibition might contribute to the protective effect 22, 23, 31 (FIG. 2) . Functional genomics of myocardial tissue has the potential to provide further insights into the mechanisms underlying IPC and other endogenous cardioprotective strategies 32 .
Clinical application
The phenomenon of IPC can be observed in a number of clinical scenarios in which the heart protects itself with brief episodes of ischaemia. 'Warm-up angina' refers to the phenomenon of increased exercise tolerance following an episode of angina after a period of rest 33 . 'Pre-infarct angina' is defined as the cardioprotective effect of antecedent angina before an acute MI resulting in smaller infarct size and improved clinical outcomes 34 .
The first clinical study conducted to test external application of an IPC stimulus in patients undergoing CABG surgery was undertaken in 1993 by our group 35 . We found that intermittent clamping and declamping of the aorta preserved myocardial ATP levels in a manner similar to that seen by Murry and colleagues, as described in their seminal paper on preconditioning 20 . Since 1993, a number of studies have confirmed the cardio protective effect of IPC by reducing the extent of PMI (as measured by serum cardiac enzymes) in patients undergoing CABG surgery. A meta-analysis of 22 trials, which included data for a total of 933 patients, found that application of IPC reduced ventricular arrhythmias, decreased inotrope requirements, and shortened the length of stay in an intensive care unit compared with control 36 . Despite these potential beneficial effects, the need to intervene on the heart directly and the inherent risk of thromboembolization arising from clamping an atherosclerotic aorta have prevented IPC from being adopted in this clinical setting.
Ischaemic postconditioning
The major disadvantage of IPC as a cardioprotective strategy is the requirement to intervene before occurrence of the ischaemic event, which is not possible in the case of an acute MI. In 2003, Zhao et al. made the exciting discovery that the heart could be protected against acute MI by interrupting myocardial reperfusion with several short-lived episodes of myocardial ischaemia, a phenomenon termed 'ischaemic postconditioning' (IPost) 23, 37, 38 . The investigators found that applying three cycles of 30-s LAD occlusion and reflow within 1 min of myocardial reperfusion could reduce MI size by 44% in canine hearts 37 . In addition to its MI-limiting effects, IPost was found to confer a Nature Reviews | Cardiology Figure 2 | Signalling pathways of ischaemic conditioning. This schema depicts the major signalling pathways and cardioprotective effects of the various forms of ischaemic conditioning. Remote ischaemic conditioning is performed by applying one or more cycles of brief ischaemia and reperfusion (IR) to the upper or lower limb by inflating and deflating a blood-pressure cuff placed on the upper arm or thigh. Through the production of a blood-borne factor(s) and the stimulation of a neural pathway, the cardioprotective signal is conveyed to the heart where prosurvival signalling pathways within the cardiomyocyte mediate the cardioprotective effect. These signalling pathways are similar to those recruited by ischaemic preconditioning and postconditioning and targeted by pharmacological cardioprotection strategies. The signalling cascade underlying cardioprotection begins at the cardiomyocyte plasma membrane with the activation of G-protein-coupled or cytokine receptors by autacoids such as adenosine, bradykinin, or opioids (released in response to the ischaemic conditioning stimulus). This process results in the recruitment of signalling pathways such as the Reperfusion Injury Salvage Kinase (RISK) pathway (PI3K-Akt and Mek1/2-Erk1/2), Survivor Activator Factor Enhancement (SAFE) pathway (TNF and JAK-STAT), and the cGMP-protein kinase G (PKG) pathway. These salvage pathways have been shown to activate downstream mediators such as endothelial nitric oxide synthase (eNOS), glycogen synthase kinase (GSK)-3β, hexokinase II (HKII), protein kinase Cε (PKCε), and the mitochondrial ATP-dependent potassium channel (K ATP ), which then mediate an inhibitory effect on mitochondrial permeability transition pore (MPTP) opening. LV, left ventricular; MI, myocardial infarction; ROS, reactive oxygen species.
myriad of protective effects, including reduced levels of myocardial oedema, oxidative stress, and polymorphonuclear neutrophil accumulation, as well as preserved endothelial function. These findings were consistent with the reduced myocardial reperfusion injury seen in postconditioned hearts 37 . Interestingly, the concept of modifying reperfusion as a strategy to limit MI size had already been introduced in the 1980s as 'gentle' 39 or 'gradual' 40 reperfusion 41 . Furthermore, the term 'postconditioning' was coined several years earlier in 1996 by Na et al. to describe the phenomenon by which intermittent reperfusioninduced by ventricular premature beats -prevented reperfusion-induced ventricular fibrillation in ischaemic feline hearts 42 . Nevertheless, the concept of IPost has captured the imagination and revitalized efforts to target myocardial reperfusion injury as a thera peutic strategy for reducing MI size. IPost has been shown to reduce MI size in rodents, rabbits, pigs, and other species, including humans, although the cardioprotective effect of IPost does not seem to be as robust as IPC 23, 24, 27, 43, 44 .
Mechanisms of action
IPost seems to share some, but not all, of the signalling mechanisms recruited at the time of reperfusion by IPC (FIG. 2) . Shared signalling elements include activation of cell-surface receptors on the cardiomyocyte (such as adenosine, bradykinin, and opioids) and recruitment of prosurvival signalling pathways (such as RISK, SAFE, and cGMP), which mediate cardio protection by preserving mitochondrial function (through reduced calcium overload, attenuated oxidative stress, and inhibited MPTP opening). Intermittent reperfusion induced by IPost has also been shown to delay restoration of intracellular pH, an effect that might contribute to the MPTP inhibition observed in postconditioned hearts 45, 46 . Interestingly, the signalling pathways underlying IPost have been demonstrated to be speciesspecific, for example the RISK pathway mediates IPost in the hearts of rats, but not those of pigs 47 . The reasons for this difference are not clear. Notably, the importance of the RISK pathway for IPost has been demonstrated by using human atrial muscle harvested from patients undergoing CABG surgery 48 .
IPost in STEMI
The ability to apply the therapeutic intervention at the onset of reperfusion in patients with STEMI has greatly facilitated the translation of IPost into the clinical setting. Only 2 years after the initial discovery of IPost, the first proof-of-concept clinical study was published 49 . In this study, IPost was performed after direct stenting within 1 min of reflow. Four episodes of 1 min inflation and 1 min deflation of an angioplasty balloon positioned upstream of the stent were performed. Investigators showed that this procedure reduced enzymatic MI size (assessed via total creatine kinase) by 36% and improved myocardial perfusion (assessed by myocardial blush grade) when compared with control 49 . In addition to providing the first evidence of successful translation of IPost into the clinical setting, findings from this study confirmed the existence of myocardial reperfusion injury in humans 50 , because it clearly demonstrated that intervening at the onset of reperfusion reduces MI size.
Since publication of this first clinical study, investigators in a number of studies have used serum troponin release 51 , myocardial single-photon emission computed tomography 52, 53 , and cardiac MRI 54 to confirm the effects of IPost on limiting the size of an MI, and have demonstrated apparent long-term benefits on cardiac function 53 . However, other studies have failed to show a beneficial effect of IPost 55 , and some researchers even report possible detrimental effects 56, 57 (TABLE 1) .
Although meta-analyses have confirmed the MI-limiting effects of IPost in patients with STEMI [58] [59] [60] , the largest clinical study (which included 700 patients) showed no beneficial effect of IPost on ST-segment resolution, peak CK-MB levels, myocardial blush grade, or MACE at 30 days Another potential issue could be the presence of confounders, such as concomitant medications (morphine, nitrates, or P2Y 12 platelet inhibitors [63] [64] [65] [66] ) and comorbidities (such as age, diabetes mellitus, hypertension, and hypercholesterolaemia), in patients with STEMI who received postconditioning. Interestingly, a retrospective analysis of 173 patients found that traditional cardiovascular risk factors in patients with STEMI -such as sex, diabetes, hypertension, dyslipidaemia, and obesity -did not affect cardioprotective efficacy of IPost 67 . However, these findings need to be confirmed in a larger, adequately powered, prospective study. In many of the studies showing positive effects, the IPost protocol was applied after direct stenting, upstream of the responsible lesion, thereby possibly avoiding coronary microembolization. By contrast, in many of the studies showing neutral or negative effects, the IPost protocol was performed after predilatation and at the site of the lesion. However, this alternative approach to the intervention was not used in all the IPost studies that showed neutral effects (TABLE 1) . A further limitation to the interpretation of the findings regarding the use of IPost is that, given the nature of the protocol, it is not possible to blind the operator to the intervention.
Whether IPost can improve clinical outcomes is not known and is being investigated in the ongoing DANAMI-3 trial 68 , the results of which will be available in early 2016. Given the invasive nature of the IPost protocol and the mixed results of clinical studies so far, the translation of IPost for the benefit of patients with STEMI might prove to be difficult.
IPost in cardiac surgery
IPost has also been investigated in patients undergoing cardiac surgery, as a therapeutic strategy for protecting against perioperative myocardial injury caused by the acute global IRI that occurs when a patient is put onto and taken off cardiopulmonary bypass. However, the protocol requires repeated cycles of aorta clamping and unclamping. This procedure is performed three times for 30 s after a patient has been taken off bypass 69, 70 . Given the invasive nature of this IPost protocol and the potential risk of thromboembolic complications from manipulating an atherosclerotic aorta, the translation of IPost for adult patients undergoing cardiac surgery might not be possible. Notably, IPost could have greater therapeutic potential in children undergoing corrective cardiac surgery for congenital heart disease, where the risk of thromboembolism is substantially lower.
Pharmacological cardioprotection
The search for a pharmacological strategy to protect the heart against acute IRI preceded the discovery of IPC by many years. The elucidation of signalling pathways underlying ischaemic conditioning has resulted in advances in the understanding of pathophysiological mechanisms of acute IRI, and has identified a number of molecular targets amenable to pharmacological manipulation 57, 61 . The history of pharmacological cardioprotection has been disappointing. Anti-inflammatory agents, antioxidants, atorvastatin, calcium-channel blockers, erythropoietin, and magnesium have all been ineffective in reducing the size of MIs and improving clinical outcomes 71 . A number of pharmacological cardio protective strategies, such as adenosine 72 and glucose-insulin-potassium therapy 73 , showed mixed results, with cardio protective efficacy depending on study design. More targeted pharmacological approaches have also failed to limit the size of MIs or improve clinical outcomes in clinical studies in which the cardioprotective effects of thera peutic hypothermia 74 , agents targeting mito chondria (bendavia 75 On a more optimistic note, a number of pharmacological strategies -such as the use of atrial natriuretic peptide, exenatide, or metoprolol -have been shown to reduce the size of an MI. Large, multicentre clinical studies are required to confirm these findings and to assess their effect on patient benefit (TABLE 2) .
Remote ischaemic conditioning A major disadvantage of IPC and IPost is that they both require an intervention to be applied directly to the heart, which is not always feasible. Therefore, a strategy in which the cardioprotective stimulus is applied to an organ or tissue remote from the heart is a far more attractive clinical application.
In 1993, Przyklenk et al. made the crucial discovery that applying the IPC stimulus in one coronary vascular territory conferred tolerance to acute IRI in a different territory, suggesting that cardioprotection elicited by IPC could be transferred from one region of the heart to another 79 . This form of intramyocardial protection was later extended beyond the heart. Investigators reported that MI size could be reduced by inducing brief ischaemia and reperfusion to either the kidney 80 or small intestine 81 immediately before the sustained coronary artery occlusion. This phenomenon has been termed remote ischaemic conditioning (RIC) [82] [83] [84] [85] [86] . The concept of RIC has been further extended to encompass different organs and tissues, thereby providing a therapeutic strategy for inter-organ protection against the detrimental effects of acute IRI. 
Mechanisms of action
The mechanism through which an episode of brief ischaemia and reperfusion in an organ or tissue located remotely from the heart exerts protection against a subsequently sustained insult of acute myocardial IRI is currently unclear. Experimental studies suggest that many of the underlying mechanistic pathways and signal transduction cascades activated within the protected organ might be similar to those recruited in the setting of IPC and IPost
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. However, the mechanistic pathway that conveys the cardio protective signal from the remote preconditioned organ or tissue to the heart remains uncertain.
Evidence indicates that a neurohumoral pathway is central to the protective effect underlying RIC. Reperfusion of the remote organ was found to be required for RIC cardioprotection, suggesting the 'washout' of a substance or humoral factor generated by the pre conditioning ischaemia, which was then transported to the heart 80, 81 . In another study, blood harvested from a rabbit previously subjected to IPC of both the heart and kidney, reduced the size of MI when transfused into a IPC-naive rabbit 87 , suggesting transfer of one or more humoral cardioprotective factors. Hexamethonium (a ganglion blocker) 81 , resection of the neural innervation of the limb 88, 89 , genetic inhibition of preganglionic vagal neurons in the brainstem 90 , and resection of the vagal nerve supply to the heart 91 have all been shown to abrogate the MI-limiting effects of limb RIC. These findings suggest that there is a requirement for an intact neural pathway to convey RIC cardioprotection, although the exact details of the neural pathway have not been completely elucidated. Stimulation of the neural pathway in the RIC-treated organ or tissue seems to be caused by local production of autacoids, such as adenosine 92, 93 and brady kinin 94 . Proteomic analysis of plasma harvested from RIC-treated animals has not identified the cardio protective factor, although evidence suggests that it is thermolabile, hydrophobic, and 3.0-8.5 kDa in size [95] [96] [97] [98] [99] . Other studies have provided experimental evidence implicating calcitonin-gene related peptide 100 , stromal cellderived factor 1 (REF. 101 ), nitrite 102 , and microRNA-144 (REF. 103 ) as possible mediators of RIC cardioprotection, although conclusive evidence is lacking. A transferrable cardioprotective factor has been isolated from plasma harvested from animals and patients after a standard limb RIC protocol 93, 98, 104 . Generation of this factor has been shown to be dependent on an intact neural pathway to the RICtreated limb 93 . Neural stimulation of the limb was achieved using direct nerve stimulation 105 , electro acupuncture 106 , 108 . Further studies are required to tease out the exact interaction between the neuronal and humoral pathways underlying RIC, and to identify the blood-borne cardioprotective factor(s) which mediate RIC cardioprotection.
Clinical application
The discovery that cardioprotection could be elicited through applying the RIC stimulus to a limb 109, 110 , by simply inflating and deflating a blood-pressure cuff placed on the upper arm or thigh 111 , has facilitated the translation of RIC into the clinical setting. The limb RIC stimulus itself has not been fully characterized. Experimental animal models most often use 5-15 min; however, the most effective limb RIC stimulus for experi mental or clinical settings remains unclear. The ability to deliver the stimulus noninvasively to the limb has allowed RIC to be delivered at different timepoints with respect to the ischaemia-reperfusion insult. RIC can be delivered 24 h (delayed remote ischaemic preconditioning or RIPC), or immediately before the index ischaemia (RIPC), after the onset of index ischaemia, but before reperfusion (remote ischaemic perconditioning or RIPerC) 112 , at the onset of reperfusion (remote ischaemic postconditioning or RIPost) 113, 114 , or even 15-30 min into reperfusion (delayed RIPost) 115 . This flexibility in timing of the RIC stimulus has enabled its application in a wide variety of clinical settings of acute IRI (FIG. 1) .
RIC in cardiac surgery. In 2000, Günaydin et al. published the first study of the effect of limb RIC in patients undergoing cardiac surgery, although in this small study of eight patients, perioperative myocardial injury (PMI) was not assessed 116 . In 2006, Cheung et al. published the first study to demonstrate a cardioprotective effect of limb RIC 117 . The study involved children undergoing cardiac surgery for congenital heart disease. Four 5-min cycles of lower limb ischaemia and reperfusion, induced by inflating and deflating a blood-pressure cuff placed on the thigh, reduced PMI (as indicated by serum troponin I level) and requirement for inotropes, and decreased airway pressure. Similar beneficial effects were reported in adults under going CABG surgery, with a 43% reduction in PMI (assessed via the 72 h area under the curve for troponin T level) 118 . However, although several studies have confirmed the beneficial effects of RIC in patients undergoing cardiac surgery in terms of attenuating PMI, a substantial number of studies have provided neutral findings (TABLE 3) . Metaanalyses seemed to confirm the cardioprotective effect of limb RIC in terms of reducing PMI [119] [120] [121] [122] , whereas several large, prospective, multi centre, randomized clinical trials (adequately powered to detect major adverse cardiovascular events) published in the past 2 years showed that limb RIC has no beneficial effects on major clinical outcomes in patients undergoing cardiac surgery [123] [124] [125] [126] (TABLE 3) .
The reasons why limb RIC is not beneficial in patients undergoing cardiac surgery are multiple and complex (TABLE 3) . Experimental data have established that RIC is most effective at protecting the heart against acute IRI. Therefore, cardiac surgery might not be the optimal setting for investigating cardioprotective therapies (because the causes of PMI are multiple). Furthermore, given that myocardial protection strategies are already being used during surgery, the magnitude of PMI is relatively small (when compared to STEMI), making it difficult to demonstrate an additional cardio protective effect. Furthermore, the optimal surgical setting for testing RIC is not known. Whether studies should have been restricted to CABG surgery alone (where acute IRI possibly has the major role in PMI) -and valve or aortic surgery (where the causes of PMI also include direct injury to the myocardium) should have been excluded -is not clear.
The most effective RIC protocol is yet to be defined. The protocol most often used in studies (four 5-min cycles of limb ischaemia-reperfusion) has been poorly characterized in both animal and clinical studies. Furthermore, whether RIC is more effective if delivered before or after surgical incision is not clear. The blinding of the investigators to the RIC protocol might have been suboptimal in many of the clinical studies reporting posi tive results 127 . Most studies achieved only incomplete blinding using a deflated cuff, instead of full blinding using a 'dummy arm' 128 . Comorbidities in patients undergoing cardiac surgery (such as age, diabetes, obesity, hypertension, hypercholesterolaemia) have been shown in animal studies to affect endogenous cardioprotective strategies such as IPC and IPost; their effect on RIC, however, has not been well defined 64 . Another consideration is that patients undergoing cardiac surgery receive a variety of drugs that can potentially affect the cardioprotective efficacy of RIC. These drugs include anaesthetics (volatile anaesthetic agents [isoflurane and sevoflurane] and propofol), analgesics (morphine), and others such as nitrates. Data from some studies suggest that RIC might be ineffective in the presence of isoflurane 129 or propofol 130 ; however, no clear association exists between the use of isoflurane or propofol and study outcome.
The majority of smaller studies documenting a cardioprotective effect showed that RIC reduces the extent of PMI defined as reduction in either peak or area-underthe-curve levels of serum cardiac enzymes. However, the magnitude of this cardioprotective effect was smaller in larger studies 131, 132 and absent in the multicentre clinical outcomes trials [124] [125] [126] . Few studies have shown a significant reduction in the incidence of CABG surgery-related MI (defined in recent clinical guidelines as type 5 MI 133 ), an end point that is a critical determinant of clinical outcomes after surgery 7 . A single reason for RIC not being of benefit in the setting of cardiac surgery might not become apparent. All the above factors probably contributed, highlighting the difficulties of translating a promising cardioprotective therapy into the clinical setting for patient benefit. . However, the aetiology of PCI-related myocardial injury is not due to acute IRI per se, but is mainly caused by acute ischaemic injury (arising from distal branch occlusions, and coronary embolization). Such complications can occur particularly after multivessel and complex PCI 134 . The first investigation of limb RIC in this clinical setting was published by ; they showed in a study including 41 patients that RIC using bilateral upper arm cuff inflations and deflations exacerbated myocardial injury 135 . In a subsequent study published in 2010, which was larger in size, Hoole et al. found that this intervention reduced the magnitude of PCI-related myocardial injury 136 . After these early studies, a number of confirmatory studies have been published, although other studies have provided neutral results (TABLE 4) .
The reasons for these discrepancies are not clear, but several factors possibly contribute. RIC has been shown to protect mainly against acute IRI, which is not a major component of PCI-related myocardial injury. Moreover, compared with stable patients, unstable patients might not benefit from RIC, because they could have been preconditioned by anginal chest pain. Comorbidities and concomitant medication might also affect RIC cardioprotection. Finally, whether simple versus multivessel or complex PCI is more amenable to RIC is not clear. The presence of predilatation or postdilatation during PCI might have attenuated any cardioprotective effect of RIC. • Largest study to show no effect with RIC on hospital outcomes AF, atrial fibrillation; AKI, acute kidney injury; AUC, area under curve; CPB, cardiopulmonary bypass; ICCF, intermittent cross-clamp fibrillation; ITU, intensive therapy unit; MI, myocardial infarction; PMI, perioperative myocardial injury; RIC, remote ischaemic conditioning.
Meta-analyses have indicated that limb RIC reduces the magnitude of PCI-related myocardial injury and decreases the incidence of PCI-related MI in stable patients undergoing PCI 119, 137 . Further multicentre studies are required to confirm these findings and determine whether this therapeutic approach can actually reduce major adverse cardiac events in patients undergoing planned PCI.
Compared with CABG surgery and PCI, the clinical setting of STEMI provides the 'purest' example of acute myocardial IRI and most closely resembles the prec linical animal models of acute myocardial IRI. Therefore, the potentially cardioprotective therapy of RIC might be best suited to patients with STEMI undergoing PPCI, especially as it can be applied in this setting to target myocardial reperfusion injury specifically. Several proof-of-concept studies have reported cardioprotective effects of limb RIC in patients with STEMI treated with PPCI (TABLE 5) . RIC seemed to be effective when given in the ambulance by paramedics 138 , on arrival at the hospital before PPCI 139, 140 , and even at the onset of reperfusion at the time of PPCI 141 . Whether limb RIC can improve clinical outcomes in patients undergoing PPCI is currently being investigated in the CONDI-2/ERIC-PPCI trial 142 . The primary outcome of this study is to determine whether RIC can reduce rates of cardiac death and hospitalization for heart failure at 12 months.
A more effective approach for targeting myocardial reperfusion injury might be to combine therapeutic interventions. This strategy has been shown to have an additive effect on reduction in size of MI in experi mental studies 143 . Initial clinical studies have found that this approach might have potential as a therapy. The combination of RIC with IPost has been shown to be more effective than IPost alone 144 (TABLES 1,5).
Other clinical settings. The heart is subjected to acute global IRI in cardiac transplantation and in cardiac arrest providing further opportunities to investigate the cardioprotective effect of limb RIC. This approach has been shown to be promising in experimental studies 145 . In particular, because there is a risk of multiorgan dysfunction arising from acute IRI in these patients, limb RIC might have the additional benefit of protecting noncardiac organs and tissues.
To date, RIC has been investigated as a one-off application; however, cumulative benefits might be accrued with repeated RIC stimuli. One experimental study demonstrated that repeating limb RIC daily for 28 days prevented adverse LV remodelling after an MI in rat hearts 146 . Whether repeated episodes of limb RIC, applied as a daily therapy, are beneficial in the clinical setting is not known. Interestingly, exercise has also been reported to induce cardioprotection and might have simi lar underlying mechanisms as RIC as a cardioprotective strategy 147 . Two clinical studies are currently underway to investigate the effect of daily RIC for 4 weeks on LV remodelling after an MI: the DREAM 148 and CRIC-RCT 149 trials. The CONDI-HF study 150 to assess the effect of daily RIC on LV ejection fraction in patients with chronic heart failure is ongoing.
Challenges facing clinical research
Although the concept of IPC was first described in 1986, the therapeutic potential of ischaemic conditioning has been realized in only the past 5-10 years, and whether the intervention can improve clinical outcomes still remains to be determined. A vast number of novel cardioprotective therapies with efficacy proven in experimental animal studies have failed to improve clinical outcomes in patients. The reasons for the failure to translate the cardioprotective effects of ischaemic conditioning strategies from the bench to bedside have been extensively discussed in the literature [151] [152] [153] [154] [155] . Briefly, this failure can be attributed to several factors. The available animal models of acute IRI are inadequate in representing the wide spectrum of comorbidities and coexisting conditions of patients with IHD (such as advanced age, diabetes, hypertension, hyperlipidaemia, other medical therapy, and pre-existing coronary artery disease) 64 . Moreover, some clinical studies were poorly designed, and investigators failed to take into account the results from experimental studies 71, 156 . Many novel cardioprotective therapies have been investigated in the clinical setting without thorough testing in preclinical animal models. Therefore, after two National Heart, Lung, and Blood Institute workshops to discuss this issue, the Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR) was formed. The objective of this consortium was to enable testing of novel cardioprotective therapies using small-animal and large-animal models of MI within a network of centres, an approach similar to a multicentre, randomized, controlled clinical trial 157, 158 . In addition, guidelines for the future design of both basic science and clinical studies for the assessment of novel cardioprotective therapies have been proposed 71, 155, 156 . The major challenge facing clinical cardioprotection research is that clinical outcomes of patients with STEMI after PPCI continue to improve, making it increasingly difficult to demonstrate a reduction in size of MI and improvement in clinical outcomes with a novel cardioprotective therapy. However, although mortality after STEMI is declining, the number of patients surviving a STEMI and subsequently developing heart failure is increasing. Therefore, novel therapeutic strategies that can prevent myocardial reperfusion injury and reduce the size of MI, to preserve LV systolic function and prevent onset of heart failure, are still needed. A similar challenge faces clinical research on cardioprotection in patients undergoing CABG surgery. Improvements in surgical techniques and advances in myocardial protection have reduced the extent of PMI together with patient mortality. Currently, the death rate at 1 year after isolated CABG surgery is as low as 1-2% 159 . However, with an ageing population and increasing prevalence of comorbidities, such as diabetes, obesity, and hypertension, novel cardioprotective therapies for high-risk patients will be required. Therefore, patients at highrisk of operative complications should perhaps be the focus of future clinical cardioprotection studies.
Conclusions
Ischaemic conditioning offers a powerful endo genous cardioprotective strategy for reducing size of MI in patients with STEMI undergoing reperfusion, and attenuating perioperative and periprocedural myocardial injury in patients undergoing CABG surgery or PCI, respectively. The different forms of ischaemic conditioning enable its application in a number of clinical settings (FIG. 1) . In particular, the simplicity and noninvasive nature, as well as the flexibility of the timing of the RIC stimulus, make it feasible to apply in many clinical scenarios involving acute IRI. Clearly, ischaemic conditioning is highly cardioprotective, as shown by the wealth of preclinical data from animal experiments. However, most importantly, clinical studies have produced mixed results. The most promising data exist for limb RIC in patients with STEMI. Results from clinical studies of pharmacological cardioprotection strategies have been generally disappointing to date. Promising agents include exenatide and metoprolol, although large, multicentre studies are required to confirm their cardioprotective potential and to determine whether they can improve clinical outcomes. Although clinical cardio protection research has been challenging, novel therapies are still needed because of the increasing preva lence of heart failure in patients with IHD. Further work is required to optimize the design of our experimental animal and clinical studies, and improve how we select which novel cardioprotective therapy to test in a clinical setting. Such advances could facilitate the discovery of new effective therapies for reducing MI size and improving clinical outcomes in patients with IHD.
